Accession Number:



Novel IgE Inhibitors for the Treatment of Food Allergies

Descriptive Note:

Technical Report,30 Sep 2014,29 Sep 2017

Corporate Author:

Leland Stanford Junior University Stanford United States

Personal Author(s):

Report Date:


Pagination or Media Count:



IgE antibodies bind the high affinity IgE Fc receptor FceRI, found primarily on mast cells and basophils, and trigger inflammatory cascades of the allergic response. Inhibitors of IgEFceRI binding have been identified and an anti-IgE therapeutic antibody omalizumab is used to treat severe allergic asthma and is being used experimentally for the treatment of food allergies. However, improved therapeutics are needed for the treatment of allergies. We are taking a two-pronged approach to developing improved therapeutics. The first approach is based on our observations that a novel class of anti-IgE inhibitors DARPins, which can actively take apart receptor complexes, exhibits improved therapeutic potency in a mouse passive cutaneous anaphylaxis model. We propose to develop novel antibody therapeutics with this disruptive activity using a systematic set of experiments. In our second approach, we are pursuing the identification of small molecule inhibitors of the IgEreceptor interaction, since this would potentially allow for the treatment of a broader patient population. We have developed and implemented novel assay tools and approaches to enable the discovery of small molecule inhibitors. We feel that both approaches have significant and complementary value and we have made good progress in our research in both areas during the past year.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: